Posted: 4 September 2023
Universal Biosensors, Inc. (ASX: UBI) is pleased to announce it has received approval from the Indian Central Drugs Standard Control Organisation (CDSCO) for the sale of Xprecia Prime, with the first order received from UBI’s distributor for the region.
This first order is in the process of being delivered and will see first sales into the market in Q3 CY23.
Mr John Sharman, CEO of UBI said; “We have been working on the approval of Xprecia Prime in India for more than 12 months, and we are delighted with this significant step forward. Whilst this first order is not material in value (under $100,000), India is a powerful and emerging market, and we are excited for the opportunities Xprecia Prime represents to disrupt this market.”
